Biotech company 10x Genomics (NASDAQ:TXG) announced better-than-expected revenue in Q1 CY2026, but sales fell by 2.6% year on year to $150.8 million. The company expects the full year’s revenue to be ...
The DNA synthesis market is witnessing strong adoption across pharmaceutical and biotechnology companies, academic and research institutes, contract research organizations (CROs), and synthetic ...
The personalized medicine market is experiencing strong growth driven by advances in genomics, biomarker-based diagnostics, and targeted therapies. The increasing prevalence of chronic diseases and ...